Naringin protects the nigrostriatal dopaminergic projection through induction of GDNF in a neurotoxin model of parkinson's disease

Journal of Nutritional Biochemistry

Volumn 25, Issue 7, 2014, Pages 801-806

  Leem, Eunju ^a   Nam, Jin Han ^d   Jeon, Min Tae ^a   Shin, Won Ho ^a,b   Won, So Yoon ^c   Park, Sang Joon ^a   Choi, Myung Sook ^a   Jin, Byung Kwan ^d   Jung, Un Ju ^a   Kim, Sang Ryong ^a  

^a Kyungpook National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Chungbuk National University   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

Author keywords

1 Methyl 4 phenylpyridinium; GDNF; Naringin; Neuroprotection; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AURANTIIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NEUROTOXIN; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; DOPAMINE; FLAVANONE DERIVATIVE; NEUROPROTECTIVE AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; FEMALE; IN VIVO STUDY; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; SURVIVAL; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; FLAVANONES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84901836821     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.03.006     Document Type: Article

References (22)

1. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744-1754.
2. Burke R.E., O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2013, 246:72-83.
3. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
4. Allen S.J., Watson J.J., Shoemark D.K., Barua N.U., Patel N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 2013, 138:155-175.
5. Pochon N.A., Menoud A., Tseng J.L., Zurn A.D., Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 1997, 9:463-471.
6. Kholodilov N., Kim S.R., Yarygina O., Kareva T., Cho J.W., Baohan A., Burke R.E. Glial cell line-derived neurotrophic factor receptor-alpha1 expressed in striatum in trans regulates development and injury response of dopamine neurons of the substantia nigra. J Neurochem 2011, 116:486-498.
7. Chauhan N.B., Siegel G.J., Lee J.M. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001, 21:277-288.
8. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 2008, 11:755-761.
9. Kim S.R., Chen X., Oo T.F., Kareva T., Yarygina O., Wang C., During M., Kholodilov N., Burke R.E. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 2011, 70:110-120.
10. Kim S.R., Kareva T., Yarygina O., Kholodilov N., Burke R.E. AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol Ther 2012, 20:275-286.
11. Altar C.A., Heikkila R.E., Manzino L., Marien M.R. 1-Methyl-4-phenylpyridine (MPP+): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation. Eur J Pharmacol 1986, 131:199-209.
12. Park E.S., Kim S.R., Jin B.K. Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress. Brain Res Bull 2012, 89:92-96.
13. Selvaraj S., Sun Y., Watt J.A., Wang S., Lei S., Birnbaumer L., Singh B.B. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest 2012, 122:1354-1367.
14. Kim H.J., Song J.Y., Park H.J., Park H.K., Yun D.H., Chung J.H. Naringin protects against rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. Korean J Physiol Pharmacol 2009, 13:281-285.
15. Golechha M., Chaudhry U., Bhatia J., Saluja D., Arya D.S. Naringin protects against kainic acid-induced status epilepticus in rats: evidence for an antioxidant, anti-inflammatory and neuroprotective intervention. Biol Pharm Bull 2011, 34:360-365.
16. Rong W., Wang J., Liu X., Jiang L., Wei F., Hu X., Han X., Liu Z. Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury. Neurochem Res 2012, 37:1615-1623.
17. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
18. Kurauchi Y., Hisatsune A., Isohama Y., Mishima S., Katsuki H. Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor. Br J Pharmacol 2012, 166:1151-1168.
19. Kim S.R., Lee D.Y., Chung E.S., Oh U.T., Kim S.U., Jin B.K. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J Neurosci 2005, 25:662-671.
20. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010, 185:1230-1237.
21. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
22. Choi B.S., Sapkota K., Kim S., Lee H.J., Choi H.S., Kim S.J. Antioxidant activity and protective effects of Tripterygium regelii extract on hydrogen peroxide-induced injury in human dopaminergic cells, SH-SY5Y. Neurochem Res 2010, 35:1269-1280.